Expansion of biosimilars in indian pharmaceutical market

Biotechnology

The introduction of biosimilars into the Indian pharmaceutical sector has the potential to significantly transform the accessibility and cost of healthcare. A viable substitute for pricey original pharmaceuticals are biosimilars, which are extremely comparable copies of currently available biological medications. This is especially true for treating chronic and crippling illnesses. India is a major player in the global biosimilars market, thanks to its thriving pharmaceutical sector and increased emphasis on innovation and research. This review paper explores the factors—such as favourable regulatory frameworks, supportive government policies, and growing domestic demand for reasonably priced biologics—that are propelling the growth of biosimilars in India. It draws attention to the roles played by Indian pharmaceutical companies in the creation and production of superior biosimilars, demonstrating their proficiency with intricate manufacturing procedures and the management of clinical trials.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.